Please ensure Javascript is enabled for purposes of website accessibility

WHO Confirms 3,100 New Confirmed Coronavirus Infections Yesterday

By Mark Prvulovic - Feb 5, 2020 at 3:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Experts are calling it the single worst day since the outbreak began.

In the latest update concerning the coronavirus, the World Health Organization (WHO) announced there were more than 3,100 new documented coronavirus infections in China yesterday. According to the health organization, this new influx of reported cases set a record, marking the single worst day since the outbreak began on Dec. 31.

This brings the total number of confirmed cases up to 24,631. Over 24,400 of them are based in mainland China, with only 11 being confirmed in the U.S. Since the outbreak began, there have been 494 deaths due to the virus.

A 3D depiction of virus cells floating among normal cells.

Image source: Getty Images.

"There are no known effective therapeutics against this 2019-nCoV and WHO recommends enrollment into a randomized controlled trial to test efficacy and safety. A master global clinical trial protocol for research and prioritization of therapeutics is ongoing at the WHO," said the organization.

A potential treatment in sight

Although there's no cure for the coronavirus at the moment, healthcare companies are working around the clock to develop a treatment, with many making significant progress. Gilead Science's (GILD 0.90%) Ebola drug, remdesivir, has shown to be fairly effective in improving patient symptoms. In response, a state-run Chinese research group, the Wuhan Institute of Virology, filed for a patent to use Gilead's drug as a potential coronavirus treatment.

Human trials using remdesivir are expected to begin as early as next week, and Gilead already shipped enough doses of the drug to China to treat 500 patients. The results from the trials aren't expected for at least a couple of months.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$63.84 (0.90%) $0.57

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.